AI in Pathology Market by Component, Neural Network, Application, End-User

List of Tables

[183 Pages Report] The AI in Pathology Market size was estimated at USD 29.01 million in 2023 and expected to reach USD 33.36 million in 2024, at a CAGR 15.33% to reach USD 78.75 million by 2030.

Global AI in Pathology Market

KEY MARKET STATISTICS
Base Year [2023]	USD 29.01 million
Estimated Year [2024]	USD 33.36 million
Forecast Year [2030]	USD 78.75 million
CAGR (%)	15.33%

Artificial intelligence (AI) in pathology integrates advanced computational techniques, machine learning algorithms, and image analysis tools to improve pathological diagnoses' speed, accuracy, and efficiency by automating various aspects of the diagnostic process. Increasing demand for accurate and quick diagnostics, the rising chronic diseases prevalence such as cancer that require timely diagnosis, and continuous developments in digital pathology infrastructure strongly contribute to the growth of the market. In addition, ongoing investments in research and development activities and supportive government initiatives aimed at promoting healthcare digitization. Furthermore, the development and integration of AI-based solutions in pathology can be an expensive affair for many healthcare organizations. Also, the usage of cloud-based solutions for sharing patient data raises concerns about data breaches and unauthorized access to sensitive information. Apart from this, rapid advancements in machine learning techniques & artificial intelligence capabilities create a potential opportunity for market growth. Additionally, emerging technologies such as blockchain can be leveraged to ensure secure storage and transfer of patient data.

Regional Insights

In the Americas, significant investments have been made in AI-driven pathology solutions to advance digital diagnostics. The Food and Drug Administration has also started approving AI-based medical devices, demonstrating an increasing acceptance of such technologies. The European Commission's program has provided significant funding for projects focusing on digital transformation in health and care. Improved healthcare infrastructure in the EU region presents a unique opportunity for AI-based pathology solutions. In the APAC region, major players have made significant investments in digital diagnostics. Government initiatives have also supported R&D in this sector, leading to numerous patents and research publications. Also, the development of healthcare infrastructure in the developing economies of the APAC region endorses the adoption of digital healthcare solutions.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the AI in Pathology Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the AI in Pathology Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the AI in Pathology Market, highlighting leading vendors and their innovative profiles. These include aetherAI, Aiforia Technologies Oyj, Akoya Biosciences, Inc., Deep Bio, Inc., Evident Corporation, F. Hoffmann-La Roche Ltd., Ibex Medical Analytics Ltd., Indica Labs, Inc., Inspirata, Inc., LUMEA, Inc., MindPeak GmbH, Nucleai Inc., OptraSCAN Inc., Paige.AI, Inc., PathAI, Inc., Proscia Inc., Techcyte, Inc., Tempus Labs, Inc., Tribun Health, Visikol, Inc. by CELLINK, and Visiopharm A/S.

Market Segmentation & Coverage

This research report categorizes the AI in Pathology Market to forecast the revenues and analyze trends in each of the following sub-markets:

Component
- Hardware
- Software
Neural Network
- Convolutional neural networks (CNNs)
- Generative adversarial networks (GANs)
- Recurrent neural networks (RNNs)
Application
- Clinical Workflow
- Disease Diagnosis & Prognosis
- Drug Discovery
- Training & Education
End-User
- Academic & Research Institutes
- Hospitals
- Pharmaceuticals & Biotechnology Companies
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the AI in Pathology Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the AI in Pathology Market?

3. What are the technology trends and regulatory frameworks in the AI in Pathology Market?

4. What is the market share of the leading vendors in the AI in Pathology Market?

5. Which modes and strategic moves are suitable for entering the AI in Pathology Market?

Product Code: MRR-1730A405FA4C

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. AI in Pathology Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing digitalization of pathology worldwide
  - 5.1.1.2. Growing need for telepathology with the prevalence of chronic disease
- 5.1.2. Restraints
  - 5.1.2.1. High cost associated with AI in pathology
- 5.1.3. Opportunities
  - 5.1.3.1. Technological advancements in AI in pathology
  - 5.1.3.2. Rising demand for personalized and customized medicine
- 5.1.4. Challenges
  - 5.1.4.1. Concerns associated with data privacy
5.2. Market Segmentation Analysis
- 5.2.1. Component: Extensive software applications in pathology for seamless workflows and efficient data management
- 5.2.2. Neural Network: Increasing generative adversarial networks adoption due to diagnostic accuracy and efficiency
- 5.2.3. Application: Wide utilization of AI in pathology for disease diagnosis to facilitate early detection of diseases
- 5.2.4. End-User: Expansion of pathology AI in pharmaceuticals & biotechnology companies for discovering potential therapeutics
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. AI in Pathology Market, by Component

6.1. Introduction
6.2. Hardware
6.3. Software

7. AI in Pathology Market, by Neural Network

7.1. Introduction
7.2. Convolutional neural networks (CNNs)
7.3. Generative adversarial networks (GANs)
7.4. Recurrent neural networks (RNNs)

8. AI in Pathology Market, by Application

8.1. Introduction
8.2. Clinical Workflow
8.3. Disease Diagnosis & Prognosis
8.4. Drug Discovery
8.5. Training & Education

9. AI in Pathology Market, by End-User

9.1. Introduction
9.2. Academic & Research Institutes
9.3. Hospitals
9.4. Pharmaceuticals & Biotechnology Companies

10. Americas AI in Pathology Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific AI in Pathology Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa AI in Pathology Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
- 13.3.1. Agreement, Collaboration, & Partnership
  - 13.3.1.1. Microsoft Collab to Build World's Largest Pathology, Oncology Imaging AI
  - 13.3.1.2. Paige and Leica Biosystems Announce Expanded Partnership to Enhance Use of Image Management and Artificial Intelligence Technology in Global Digital Pathology Workflows
- 13.3.2. New Product Launch & Enhancement
  - 13.3.2.1. PathAI Announces PathExplore, an AI-powered Pathology Panel to Unlock Untapped Insights from the Tumor Microenvironment

14. Competitive Portfolio

14.1. Key Company Profiles
- 14.1.1. aetherAI
- 14.1.2. Aiforia Technologies Oyj
- 14.1.3. Akoya Biosciences, Inc.
- 14.1.4. Deep Bio, Inc.
- 14.1.5. Evident Corporation
- 14.1.6. F. Hoffmann-La Roche Ltd.
- 14.1.7. Ibex Medical Analytics Ltd.
- 14.1.8. Indica Labs, Inc.
- 14.1.9. Inspirata, Inc.
- 14.1.10. LUMEA, Inc.
- 14.1.11. MindPeak GmbH
- 14.1.12. Nucleai Inc.
- 14.1.13. OptraSCAN Inc.
- 14.1.14. Paige.AI, Inc.
- 14.1.15. PathAI, Inc.
- 14.1.16. Proscia Inc.
- 14.1.17. Techcyte, Inc.
- 14.1.18. Tempus Labs, Inc.
- 14.1.19. Tribun Health
- 14.1.20. Visikol, Inc. by CELLINK
- 14.1.21. Visiopharm A/S
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing